Abstract
In this review, we evaluate the role of fluid biomarkers related to neurodegenerative diseases. Such conditions present diagnostic challenges due to phenotypic heterogeneity, longitudinal evolution, overlap between diagnostic entities, and variability in progression. Biomarkers can potentially provide insight into diagnosis, progression, prognostication, and treatment efficacy. This review covers recent advances in fluid biomarkers including beta-amyloid, tau protein, neurofilament light chain, alpha-synuclein and glial fibrillary protein, and briefly touches upon imaging biomarkers. For each biomarker, we discuss the pathophysiological correlates, clinical uses, accuracy, and limitations.
| Original language | English |
|---|---|
| Article number | 100062 |
| Journal | Biomarkers in Neuropsychiatry |
| Volume | 8 |
| DOIs | |
| State | Published - Jun 2023 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Alzheimer's Disease
- Biomarkers
- Cerebrospinal Fluid
- Diagnosis
- Neurodegenerative Disease
- Plasma
Fingerprint
Dive into the research topics of 'Fluid biomarkers for the diagnosis of neurodegenerative diseases'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver